A deep dive into future therapies for microcytic anemias and clinical considerations.

François Rodrigues, Tereza Coman, Guillemette Fouquet, Francine Côté, Geneviève Courtois, Thiago Trovati Maciel, Olivier Hermine

Journal: Expert review of hematology 2023;16(5):349-364

PMID: 37092971

Abstract

INTRODUCTION

Microcytic anemias (MA) have frequent or rare etiologies. New discoveries in understanding and treatment of microcytic anemias need to be reviewed.

AREAS COVERED

Microcytic anemias with a focus on the most frequent causes and on monogenic diseases that are relevant for understanding biocellular mechanisms of MA. All treatments except gene therapy, with a focus on recent advances. PubMed search with references selected by expert opinion.

EXPERT OPINION

As the genetic and cellular backgrounds of dyserythropoiesis will continue to be clarified, collaboration with bioengineering of treatments acting specifically at the protein domain level will continue to provide new therapies in hematology as well as oncology and neurology.

Address: Université de Paris, service d'hématologie adultes, Hôpital Necker - Enfants Malades, France.; Inserm U1163, CNRS ERL8254 Imagine Institute, Paris, France.; Département d'hématologie, Institut Gustave Roussy, Villejuif, France.; Hématologie clinique, Centre Hospitalier Sud Francilien, Corbeil Essonnes, France.

Link outs

Free resources

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.